GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Sarepta Therapeutics Inc (NAS:SRPT) » Definitions » Cyclically Adjusted PS Ratio

Sarepta Therapeutics (Sarepta Therapeutics) Cyclically Adjusted PS Ratio : 18.94 (As of Apr. 30, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Sarepta Therapeutics Cyclically Adjusted PS Ratio?

As of today (2024-04-30), Sarepta Therapeutics's current share price is $128.80. Sarepta Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was $6.80. Sarepta Therapeutics's Cyclically Adjusted PS Ratio for today is 18.94.

The historical rank and industry rank for Sarepta Therapeutics's Cyclically Adjusted PS Ratio or its related term are showing as below:

SRPT' s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 10.07   Med: 25.86   Max: 98.48
Current: 18.92

During the past years, Sarepta Therapeutics's highest Cyclically Adjusted PS Ratio was 98.48. The lowest was 10.07. And the median was 25.86.

SRPT's Cyclically Adjusted PS Ratio is ranked worse than
82.81% of 506 companies
in the Biotechnology industry
Industry Median: 5.395 vs SRPT: 18.92

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Sarepta Therapeutics's adjusted revenue per share data for the three months ended in Dec. 2023 was $3.824. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is $6.80 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Sarepta Therapeutics Cyclically Adjusted PS Ratio Historical Data

The historical data trend for Sarepta Therapeutics's Cyclically Adjusted PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sarepta Therapeutics Cyclically Adjusted PS Ratio Chart

Sarepta Therapeutics Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 56.29 58.37 23.38 25.31 14.17

Sarepta Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 25.31 24.96 19.36 18.98 14.17

Competitive Comparison of Sarepta Therapeutics's Cyclically Adjusted PS Ratio

For the Biotechnology subindustry, Sarepta Therapeutics's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Sarepta Therapeutics's Cyclically Adjusted PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Sarepta Therapeutics's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Sarepta Therapeutics's Cyclically Adjusted PS Ratio falls into.



Sarepta Therapeutics Cyclically Adjusted PS Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.

Sarepta Therapeutics's Cyclically Adjusted PS Ratio for today is calculated as

Cyclically Adjusted PS Ratio=Share Price/ Cyclically Adjusted Revenue per Share
=128.80/6.8
=18.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sarepta Therapeutics's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Sarepta Therapeutics's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare=Revenue per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=3.824/129.4194*129.4194
=3.824

Current CPI (Dec. 2023) = 129.4194.

Sarepta Therapeutics Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 0.161 99.695 0.209
201406 0.065 100.560 0.084
201409 0.026 100.428 0.034
201412 0.001 99.070 0.001
201503 0.000 99.621 0.000
201506 0.000 100.684 0.000
201509 0.000 100.392 0.000
201512 0.028 99.792 0.036
201603 0.000 100.470 0.000
201606 0.000 101.688 0.000
201609 0.000 101.861 0.000
201612 0.099 101.863 0.126
201703 0.292 102.862 0.367
201706 0.637 103.349 0.798
201709 0.747 104.136 0.928
201712 0.898 104.011 1.117
201803 1.000 105.290 1.229
201806 1.123 106.317 1.367
201809 1.185 106.507 1.440
201812 1.230 105.998 1.502
201903 1.213 107.251 1.464
201906 1.280 108.070 1.533
201909 1.335 108.329 1.595
201912 1.343 108.420 1.603
202003 1.487 108.902 1.767
202006 1.762 108.767 2.097
202009 1.833 109.815 2.160
202012 1.839 109.897 2.166
202103 1.849 111.754 2.141
202106 2.058 114.631 2.323
202109 2.371 115.734 2.651
202112 2.344 117.630 2.579
202203 2.416 121.301 2.578
202206 2.668 125.017 2.762
202209 2.628 125.227 2.716
202212 2.942 125.222 3.041
202303 2.875 127.348 2.922
202306 2.944 128.729 2.960
202309 3.733 129.860 3.720
202312 3.824 129.419 3.824

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Sarepta Therapeutics  (NAS:SRPT) Cyclically Adjusted PS Ratio Explanation

Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.


Sarepta Therapeutics Cyclically Adjusted PS Ratio Related Terms

Thank you for viewing the detailed overview of Sarepta Therapeutics's Cyclically Adjusted PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Sarepta Therapeutics (Sarepta Therapeutics) Business Description

Traded in Other Exchanges
Address
215 First Street, Suite 415, Cambridge, MA, USA, 02142
Sarepta Therapeutics Inc is a biotechnology company focused on treating rare, infectious, and other diseases. It targets a broad range of diseases while focusing on the rapid development of its drug candidates. Sarepta's strategy involves proprietary RNA-targeted technology platforms to be used for developing novel pharmaceutical products to treat a broad range of diseases and address key unmet medical needs. The company uses third-party contractors to manufacture its product candidates. Most of Sarepta's product candidates are at an early stage of development.
Executives
Richard Barry director 285 MARGALITA DRIVE, SAN RAFAEL CA 94901
Douglas S Ingram director, officer: President & CEO 2525 DUPONT DR, IRVINE CA 92612
Michael Andrew Chambers director 215 FIRST STREET, CAMBRIDGE MA 02142
Wigzell Hans Lennart Rudolf director OSKAR BAECKSTROMSV.11, HAGERSTEN V7 12935
Bilal Arif officer: Chief Tech Ops Officer 215 FIRST STREET, CAMBRIDGE MA 02129
Stephen Mayo director 2000 GALLOPING HILL RD, KENILWORTH NJ 07033
Kathryn Jean Boor director 3736 S. MAIN STREET, MARION NY 14505
Louise Rodino-klapac officer: Chief Scientific Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
M Kathleen Behrens director 6701 KAISER DRIVE, FREMONT CA 94555
Ryan Edward Brown officer: SVP, General Counsel 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Ian Michael Estepan officer: Chief Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
Joseph Bratica officer: Principal Financial Officer 215 FIRST STREET, STE 415, CAMBRIDGE MA 02142
David T Howton officer: SVP, General Counsel VERTEX PHARMACEUTICALS INCORPORATED, 130 WAVERLY STREET, CAMBRIDGE MA 02139
John C Martin director 333 LAKESIDE DRIVE, FOSTER CITY X1 94404
Sandesh Mahatme officer: Senior Vice President, CFO C/O CELGENE CORPORATION, 86 MORRIS AVENUE, SUMMIT NJ 07901